Skip to main content
Log in

Human papillomavirus 16 and 18 L1 serology in Korean women with high-grade cervical intraepithelial neoplasia and cervical cancer

  • Research Articles
  • Drug Actions
  • Published:
Archives of Pharmacal Research Aims and scope Submit manuscript

Abstract

We aimed to determine the prevalence of HPV-16/18 antibodies in Korean women with high-grade cervical intraepithelial neoplasia (CIN) and cervical cancer. We conducted the hospital-based case-control study at the university hospital between 2003 and 2006. Cases were 130 high-grade CIN and 43 cervical cancer patients and the control group was 106 women showing normal cervical cytology. Enzyme-linked immunosorbent assays were performed for HPV-16/18 L1 virus-like particles (VLPs) as an antigen. Seropositivity for HPV-16 VLP and HPV-18 VLP was found in 67.4% and 30.2% of cancer patients and 59.2% and 20.0% of high-grade CIN patients, respectively. Seropositivity for HPV-16 with high-grade CIN (OR 6.91; 95% CI 3.74–12.76) and cervical cancer (OR 8.99; 95% CI 3.88–20.84) presented significant associations, as did seropositivity for HPV-18 (high-grade CIN: OR 3.64; 95% CI 1.67–7.95, cervical cancer: OR 6.82; 95% CI 2.52–18.45). Patients with both HPV-16 and 18 seropositivity were 9.38 times (95% CI 2.98–29.51) more likely to have high-grade CIN and 17.05 times (95% CI 4.55–63.87) more likely to have cancer. Both HPV 16 and 18 L1 VLP serology is the clear disease predictors of presence of high-grade CIN and cervical cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Bosch, F. X., Manos, M. M., Munoz, N., Sherman, M., Jansen, A. M., Peto, J., Schiffman, M. H., Moreno, V., Kurman, R., and Shah, K. V., Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J. Natl. Cancer Inst., 87, 796–802 (1995).

    Article  PubMed  CAS  Google Scholar 

  • Carter, J. J., Koutsky, L. A., Hughes, J. P., Lee, S. K., Kuypers, J., Kiviat, N., and Galloway, D. A., Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J. Infect. Dis., 181, 1911–1919 (2000).

    Article  PubMed  CAS  Google Scholar 

  • Clifford, G. M., Shin, H. R., Oh, J. K., Waterboer, T., Ju, Y. H., Vaccarella, S., Quint, W., Pawlita, M., and Franceschi, S., Serologic response to oncogenic human papillomavirus types in male and female university students in Busan, South Korea. Cancer Epidemiol. Biomarkers. Prev., 16, 1874–1879 (2007).

    Article  PubMed  CAS  Google Scholar 

  • Combita, A. L., Bravo, M. M., Touze, A., Orozco, O., and Coursaget, P., Serologic response to human oncogenic papillomavirus types 16, 18, 31, 33, 39, 58 and 59 viruslike particles in colombian women with invasive cervical cancer. Int. J. Cancer, 97, 796–803 (2002).

    Article  PubMed  CAS  Google Scholar 

  • De Gruijl, T. D., Bontkes, H. J., Walboomers, J. M., Schiller, J. T., Stukart, M. J., Groot, B. S., Chabaud, M. M., Remmink, A. J., Verheijen, R. H., Helmerhorst, T. J., Meijer, C. J., and Scheper, R. J., Immunoglobulin G responses against human papillomavirus type 16 virus-like particles in a prospective nonintervention cohort study of women with cervical intraepithelial neoplasia. J. Natl. Cancer Inst., 89, 630–638 (1997).

    Article  PubMed  Google Scholar 

  • Dillner, J., The serological response to papillomaviruses. Semin. Cancer Biol., 9, 423–430 (1999).

    Article  PubMed  CAS  Google Scholar 

  • Einstein, M. H., Studentsov, Y. Y., Ho, G. Y., Fazzari, M., Marks, M., Kadish, A. S., Goldberg, G. L., Runowicz, C. D., and Burk, R. D., Combined human papillomavirus DNA and human papillomavirus-like particle serologic assay to identify women at risk for high-grade cervical intraepithelial neoplasia. Int. J. Cancer, 120, 55–59 (2007).

    Article  PubMed  CAS  Google Scholar 

  • Franco, E. L., Rohan, T. E., and Villa, L. L., Epidemiologic evidence and human papillomavirus infection as a necessary cause of cervical cancer. J. Natl. Cancer Inst., 91, 506–511 (1999).

    Article  PubMed  CAS  Google Scholar 

  • Hinchliffe, S. A., Van Velzen, D., Korporaal, H., Kok, P. L., and Boon, M. E., Transience of cervical HPV infection in sexually active, young women with normal cervicovaginal cytology. Br. J. Cancer, 72, 943–945 (1995).

    PubMed  CAS  Google Scholar 

  • Ho, G. Y., Studentsov, Y. Y., Bierman, R., and Burk, R. D., Natural history of human papillomavirus type 16 viruslike particle antibodies in young women. Cancer Epidemiol. Biomarkers Prev., 13, 110–116 (2004).

    Article  PubMed  CAS  Google Scholar 

  • Kim, S. N., Jeong, H. S., Park, S. N., and Kim, H. J., Purification and immunogenicity study of human papillomavirus type 16 L1 protein in Saccharomyces cerevisiae. J. Virol. Methods, 139, 24–30 (2007).

    Article  PubMed  CAS  Google Scholar 

  • Kirnbauer, R., Hubbert, N. L., Wheeler, C. M., Becker, T. M., Lowy, D. R., and Schiller, J. T., A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16. J. Natl. Cancer Inst., 86, 494–9 (1994).

    Article  PubMed  CAS  Google Scholar 

  • Koutsky, L. A., Holmes, K. K., Critchlow, C. W., Stevens, C. E., Paavonen, J., Beckmann, A. M., Derouen, T. A., Galloway, D. A., Vernon, D., and Kiviat, N. B., A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N. Engl. J. Med., 327, 1272–1278 (1992).

    PubMed  CAS  Google Scholar 

  • Le Cann, P., Touze, A., Enogat, N., Leboulleux, D., Mougin, C., Legrand, M. C., Calvet, C., Afoutou, J. M., and Coursaget, P., Detection of antibodies against human papillomavirus (HPV) type 16 virions by enzyme-linked immunosorbent assay using recombinant HPV 16 L1 capsids produced by recombinant baculovirus. J. Clin. Microbiol., 33, 1380–1382 (1995).

    PubMed  CAS  Google Scholar 

  • Marais, D. J., Rose, R. C., Lane, C., Kay, P., Nevin, J., Denny, L., Soeters, R., Dehaeck, C. M., and Williamson, A. L., Seroresponses to human papillomavirus types 16, 18, 31, 33, and 45 virus-like particles in South African women with cervical cancer and cervical intraepithelial neoplasia. J. Med. Virol., 60, 403–410 (2000).

    Article  PubMed  CAS  Google Scholar 

  • Nonnenmacher, B., Kruger Kjaer, S., Svare, E. I., Scott, J. D., Hubbert, N. L., Van Den Brule, A. J., Kirnbauer, R., Walboomers, J. M., Lowy, D. R., and Schiller, J. T., Seroreactivity to HPV16 virus-like particles as a marker for cervical cancer risk in high-risk populations. Int. J. Cancer, 68, 704–709 (1996).

    Article  PubMed  CAS  Google Scholar 

  • Sasagawa, T., Yamazaki, H., Dong, Y. Z., Satake, S., Tateno, M., and Inoue, M., Immunoglobulin-A and -G responses against virus-like particles (VLP) of human papillomavirus type 16 in women with cervical cancer and cervical intra-epithelial lesions. Int. J. Cancer, 75, 529–535 (1998).

    Article  PubMed  CAS  Google Scholar 

  • Skiba, D., Mehlhorn, G., Fasching, P. A., Beckmann, M. W., and Ackermann, S., Prognostic significance of serum antibodies to HPV-16 L1 virus-like particles in patients with invasive cervical cancer. Anticancer Res., 26, 4921–4926 (2006).

    PubMed  CAS  Google Scholar 

  • Sun, Y., Eluf-Neto, J., Bosch, F. X., Munoz, N., Walboomers, J. M., Meijer, C. J., Shah, K. V., Clayman, B., and Viscidi, R. P., Serum antibodies to human papillomavirus 16 proteins in women from Brazil with invasive cervical carcinoma. Cancer Epidemiol. Biomarkers Prev., 8, 935–940 (1999).

    PubMed  CAS  Google Scholar 

  • Tabrizi, S. N., Frazer, I. H., and Garland, S. M., Serologic response to human papillomavirus 16 among Australian women with high-grade cervical intraepithelial neoplasia. Int. J. Gynecol. Cancer, 16, 1032–1035 (2006).

    Article  PubMed  CAS  Google Scholar 

  • Trottier, H., Mahmud, S., Prado, J. C., Sobrinho, J. S., Costa, M. C., Rohan, T. E., Villa, L. L., and Franco, E. L., Type-specific duration of human papillomavirus infection: implications for human papillomavirus screening and vaccination. J. Infect. Dis., 197, 1436–1447 (2008).

    Article  PubMed  Google Scholar 

  • Wideroff, L., Schiffman, M., Haderer, P., Armstrong, A., Greer, C. E., Manos, M. M., Burk, R. D., Scott, D. R., Sherman, M. E., Schiller, J. T., Hoover, R. N., Tarone, R. E., and Kirnbauer, R., Seroreactivity to human papillomavirus types 16, 18, 31, and 45 virus-like particles in a case-control study of cervical squamous intraepithelial lesions. J. Infect. Dis., 180, 1424–1428 (1999).

    Article  PubMed  CAS  Google Scholar 

  • Woo, M. K., An, J. M., Kim, J. D., Park, S. N., and Kim, H. J., Expression and purification of human papillomavirus 18 L1 virus-like particle from saccharomyces cerevisiae. Arch. Pharm. Res., 31, 205–209 (2008).

    Article  PubMed  CAS  Google Scholar 

  • Woo, M. K., Hur, S. J., Park, S., and Kim, H. J. Study of cell-mediated response in mice by HPV16 L1 virus-like particles expressed in Saccharomyces cerevisiae. J. Microbiol. Biotechnol., 17, 1738–1741 (2007).

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Hong-Jin Kim.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jeong, NH., Woo, MK., Lee, NW. et al. Human papillomavirus 16 and 18 L1 serology in Korean women with high-grade cervical intraepithelial neoplasia and cervical cancer. Arch. Pharm. Res. 32, 1013–1018 (2009). https://doi.org/10.1007/s12272-009-1706-z

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12272-009-1706-z

Key words

Navigation